Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT03377179 2025-07-23

A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma

Phase 2 Completed

65 enrolled

Gastrointestinal

Cholangiocarcinoma, Klatskin Tumor

NCT03250273 2025-05-28

A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Phase 2 Completed

44 enrolled 19 charts

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms, Cholangiocarcinoma

NCT05239169 2025-05-01

Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

Phase 2 Completed

40 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT02699606 2025-04-27

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

Phase 2 Completed

35 enrolled

GastrointestinalThoracic

Acrocephalosyndactylia, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Cholangiocarcinoma

NCT01862315 2025-03-19

Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)

Phase 2 Completed

55 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT04907851 2025-03-17

KEYNOTE-E86

Phase 2 Completed

45 enrolled 25 charts

Gastrointestinal

Biliary Tract Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

NCT05010668 2025-02-21

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Phase 2 Completed

28 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT04306367 2025-02-17

Study of Pembrolizumab and Olaparib in Bile Duct Cancer

Phase 2 Completed

14 enrolled 13 charts

Gastrointestinal

Cholangiocarcinoma

NCT05236699 2025-02-14

CCGLC-005

Phase 2 Completed

23 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT04361331 2025-02-07

Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma

Phase 2 Completed

61 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT04919642 2024-06-25

Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

Phase 2 Completed

55 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT05518071 2024-06-24

FLUOPANC

Phase 2 Completed

20 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT04256980 2024-05-30

Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement

Phase 2 Completed

34 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT03201458 2024-04-05

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

Phase 2 Completed

86 enrolled 16 charts

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT04059562 2024-03-27

TRITICC

Phase 2 Completed

28 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT03339843 2024-03-15

MiMe-A

Phase 2 Completed

85 enrolled

GastrointestinalGenitourinaryGynecologic

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Neoplasms, Urologic Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT03230318 2023-12-19

FIDES-01

Phase 2 Completed

148 enrolled 15 charts

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Liver Neoplasms, Cholangiocarcinoma

NCT02232633 2023-11-14

A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer

Phase 2 Completed

45 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT03833661 2023-10-25

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

Phase 2 Completed

159 enrolled 23 charts

Gastrointestinal

Biliary Tract Neoplasms, Camurati-Engelmann Syndrome, Gallbladder Neoplasms, Cholangiocarcinoma

NCT03207347 2023-09-15

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

Phase 2 Completed

37 enrolled 15 charts

DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Mesothelioma, Cholangiocarcinoma

NCT03003065 2023-08-22

PDT

Phase 2 Completed

10 enrolled

Gastrointestinal

Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT03278106 2023-06-28

TAS-102 in Treating Advanced Biliary Tract Cancers

Phase 2 Completed

28 enrolled 12 charts

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT02520141 2023-06-15

Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery

Phase 2 Completed

61 enrolled 9 charts

Gastrointestinal

Gallbladder Neoplasms, Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT03473574 2023-06-15

IMMUCHEC

Phase 2 Completed

128 enrolled

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT03895970 2023-03-29

Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors

Phase 2 Completed

32 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT02821754 2023-03-28

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Phase 2 Completed

54 enrolled 14 charts

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Cholangiocarcinoma

NCT03801915 2023-03-21

Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

Phase 2 Completed

10 enrolled 14 charts

Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

NCT00286013 2022-12-09

Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma

Phase 2 Completed

24 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT03079427 2022-12-06

Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma

Phase 2 Completed

101 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT03769753 2022-09-10

Trial of IRE in Cholangiocarcinoma

Phase 2 Completed

8 enrolled 6 charts

Gastrointestinal

Cholangiocarcinoma

NCT02392637 2022-02-02

Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers

Phase 2 Completed

62 enrolled 10 charts

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT03111732 2021-12-03

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

Phase 2 Completed

11 enrolled 16 charts

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Liver Neoplasms, Cholangiocarcinoma

NCT03486678 2021-10-28

SHR-1210 in Combination With GEMOX in Patients With Advanced BTC

Phase 2 Completed

38 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT02631590 2021-08-04

Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma

Phase 2 Completed

24 enrolled 11 charts

Gastrointestinal

Digestive System Neoplasms, Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

NCT04656249 2021-06-04

LENABC

Phase 2 Completed

46 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

Clinical Trials

DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion

Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

18F-FAPI-74 GI

HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC

Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment

NIFE

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

KEYVIBE-005

A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma

A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)

KEYNOTE-E86

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Study of Pembrolizumab and Olaparib in Bile Duct Cancer

CCGLC-005

Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma

Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

FLUOPANC

Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

TRITICC

MiMe-A

FIDES-01

A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

PDT

TAS-102 in Treating Advanced Biliary Tract Cancers

Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery

IMMUCHEC

Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma

Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma

Trial of IRE in Cholangiocarcinoma

Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

SHR-1210 in Combination With GEMOX in Patients With Advanced BTC

Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma

LENABC